Growth-factor doping agents (FGF / HGF / PDGF / VEGF / MGF)
Muscle & Strength · Growth factor / tissue-remodeling signal
Tier F
What this is
WADA coverage: fibroblast growth factors/FGFs, hepatocyte growth factor/HGF, mechano growth factors/MGFs, platelet-derived growth factor/PDGF and vascular endothelial growth factor/VEGF. Dihexa is a separate HGF/c-Met-adjacent nootropic row; this row covers direct growth-factor doping concepts. Additional WADA alias coverage: Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues; Thymosin-beta4 and its derivatives.
Mechanism
Growth-factor pathways are marketed for repair, angiogenesis, hypertrophy or regeneration, but systemic enhancement use is largely speculative and biologically high-risk.
Dose & route
No approved enhancement dose
Citations
- https://www.ncbi.nlm.nih.gov/books/NBK305894/
- https://www.wada-ama.org/en/resources/2026-prohibited-list
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.